OncoMatch/Clinical Trials/NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Is NCT05583617 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for multiple myeloma.
Treatment: Cevostamab · Lenalidomide · Tocilizumab · Iberdomide · Dexamethasone — CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: autologous stem cell transplant
Autologous Stem Cell Transplant (SCT) within 100 days prior to first study treatment and the absence of progressive disease
Must have received: proteasome inhibitor — relapsed/refractory
Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available
Must have received: immunomodulatory drug — relapsed/refractory
Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available
Must have received: anti-CD38 antibody — relapsed/refractory
Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available
Cannot have received: investigational medicinal product
Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies received previously in CO43923 (any arms) within 5 half-lives or 3 weeks whichever is the shortest
Cannot have received: investigational medicinal product
Prior treatment with any investigational medicinal product, systemic cancer therapy, or immunotherapies in any arm of study CO43923 within 5 half-lives or 3 weeks, whichever is shorter
Cannot have received: investigational medicinal product
Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies within 5 half-lives or 12 weeks before starting pre-phase
Cannot have received: CAR-T cell therapy
Exception: within 12 weeks before starting pre-phase
Prior treatment with CAR T-cell therapy (autologous or allogeneic) within 12 weeks before starting pre-phase
Cannot have received: autologous stem cell transplant
Exception: within 100 days prior to starting pre-phase
Autologous SCT within 100 days prior to starting pre-phase
Cannot have received: allogeneic stem cell transplant
Prior allogeneic SCT
Cannot have received: FcRH5-targeting agent (cevostamab)
Prior treatment with cevostamab or another agent targeting FcRH5 or iberdomide
Cannot have received: CRBN modulating agent (iberdomide)
Prior treatment with cevostamab or another agent targeting FcRH5 or iberdomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify